An­nex­on grabs $75M to pay for push in­to PhII stud­ies for C1q drugs

Back when Bain’s Ricky Sun worked at Bio­gen, he gained a deep ap­pre­ci­a­tion for the role of the clas­si­cal com­ple­ment path­way in neu­rode­gen­er­a­tion. And now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.